Apimeds Pharmaceuticals US Overview

Apimeds Pharmaceuticals US Selling, General & Admin

Selling, General & Admin expenses for APUS.

Quarterly SG&A Expenses

$11.28M

↑ 2997.02% YoY

As of Mar 31, 2026

Annual SG&A Expenses (TTM)

$10.29B

↑ 752303.62% YoY

Trailing 12 months ending Mar 31, 2026

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin